NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01569295,Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ),https://clinicaltrials.gov/study/NCT01569295,Tugela,COMPLETED,The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL),YES,Chronic Lymphocytic Leukemia,DRUG: Idelalisib|DRUG: Rituximab|DRUG: Bendamustine|DRUG: Placebo to match idelalisib,"Progression-Free Survival (PFS), PFS was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. PFS (months) = (minimum (date of disease progression, date of death) - date of randomization + 1)/30.4375., Up to 84 months","Overall Response Rate (ORR), ORR was the percentage of participants who achieved a complete response (CR), CR with incomplete marrow recovery (CRi,) or partial response (PR) and maintained the response for at least 12 weeks. CR was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy.

PR was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors. CRi was defined as all criteria for CR met but with persistent anemia, thrombocytopenia, neutropenia or a hypocellular bone marrow., Up to 84 months|Lymph Node Response Rate, Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lesions., Up to 84 months|Overall Survival, Overall survival (OS) was defined as the interval from randomization to death from any cause. Overall survival (months) = (date of death - date of randomization + 1)/30.4375., Up to 84 months|Complete Response Rate, Complete response (CR) rate was defined as the percentage of participants who achieved a CR., Up to 84 months",,Gilead Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE3,416,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",GS-US-312-0115|2011-006292-20,2012-06-15,2019-06-10,2019-06-10,2012-04-03,2018-02-27,2020-03-10,"Clearview Cancer Institute, Huntsville, Alabama, 35805, United States|UCLA Medical Center, Los Angeles, California, 90095, United States|Stanford Cancer Center, Palo Alto, California, 94035, United States|Rocky Mountain Cancer Center, Denver, Colorado, 80218, United States|University of Florida, Gainesville, Florida, 32603, United States|Winship Cancer Institute at Emory University, Atlanta, Georgia, 30322, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Summit Medical Group, P.A., Morristown, New Jersey, 07962, United States|North Shore University Hospital, Manhasset, New York, 11030, United States|Long Island Jewish Medical Center, New Hyde Park, New York, 11042, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10021, United States|Columbia University Medical Center, New York, New York, 10032, United States|Willamette Valley Cancer Center, Eugene, Oregon, 97477, United States|Charleston Hematology Oncology, Charleston, South Carolina, 29414, United States|Texas Oncology, Austin, Texas, 78731, United States|Texas Oncology PA, Dallas, Texas, 75246, United States|Texas Oncology, Fort Worth, Texas, 76104, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Cancer Care Northwest, US Oncology, Spokane, Washington, 99202, United States|Virginia Cancer Specialists, PC, Vancouver, Washington, 98684, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|St Vincent's Hospital - Sydney, Darlinghurst, New South Wales, 2010, Australia|Gosford Hospital, Gosford, New South Wales, 2250, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Monash Medical Centre - Clayton Campus, Clayton, Victoria, 3168, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Princess Alexandra Hospital, Woolloongabba, 4102, Australia|Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg, Antwerpen, 2060, Belgium|UZ Gent, Gent, 9000, Belgium|UZ Leuven, Leuven, 3000, Belgium|Cancer Care Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada|Clinical Hospital ""Dubrava"", Zagreb, 10000, Croatia|Klinichki Bolnicki Centar-Zagreb, Zagreb, 10000, Croatia|University Hospital Merkur, Zagreb, 10000, Croatia|Fakultni nemocnice Brno, Brno, 625 00, Czechia|Fakultní nemocnice Hradec Králové, Hradec Králové, 500 05, Czechia|Fakultni nemocnice Ostrava, Ostrava, 708 52, Czechia|Hopital Henri Mondor, Créteil, 94010, France|Centre Jean Bernard - Clinique Victor Hugo, Le Mans cedex, 72015, France|CHRU Lille-Hôpital Claude Huriez, Lille, 59045, France|Centre Léon Bérard - Centre régional de lutte contre le cancer Rhône-Alpes, Lyon, 69373, France|Centre Hospitalier de Mulhouse, Mulhouse, 68100, France|CHU Hôtel-Dieu-Service Hématologie, Nantes, 44 093, France|Centre Hospitalier Lyon Sud, Pierre Bénite, Pierre Bénite, France|Hopital Purpan, Toulouse, 31059, France|Hôpitaux de Brabois, Vandoeuvre-lés-Nancy, 54511, France|G. Genimatas Hospital, Athens, 11527, Greece|University General Hospital of Patras, Patras, 26500, Greece|Semmelweis Egyetem, Budapest, 1083, Hungary|Országos Onkológiai Intézet, Budapest, 1122, Hungary|Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Debrecen, 4032, Hungary|Tallian Gyula utca 20-32, Kaposvár, 7400, Hungary|Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ, Szeged, 6720, Hungary|Mater Misericordiae Hospital, Dublin, Ireland|Spedali Civili di Brescia, Brescia, 25123, Italy|Ospedale Oncologico Regionale A. Businco, Cagliari, 9121, Italy|IRCCS Ospedale San Raffaele, Milano, 20132, Italy|Azienda Ospedaliera Universitaria San Giovanni Battista-Molinette, Torino, 10126, Italy|Szpital Specjalistyczny w Brzozowie, Brzozow, 36-200, Poland|Malopolskie Centrum Medyczne, Krakow, 30-510, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, 93-510, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1, Lublin, 20-081, Poland|Wojewodzki Szpital w Opolu, Opole, 43-372, Poland|Centralny Szpital Kliniczny MSW w Warszawie, Warszawa, 02-507, Poland|Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie, Warszawa, 02-781, Poland|Hospital Santa Maria, Lisboa, 1649-035, Portugal|""Instituto Portugues de Oncologia do Porto Francisco Gentil (IPOPFG, EPE), Porto, 4200-072, Portugal|Emergency County Clinical Hospital Brasov, Brasov, 500152, Romania|""Colentina"" Clinical Hospital, Bucharest, 20125, Romania|""Fundeni"" Clinical Institute, Bucharest, 22328, Romania|Regional Oncology Institute Iasi, Iasi, 700483, Romania|Russian Oncology Research Center (N.N. Blokhin), Moscow, 115478, Russian Federation|Nizhegorodskaya Regional Clinical Hospital n.a. N.A. Semashko, Nizhniy Novgorod, 603126, Russian Federation|Novosibirsk State Regional Clinical Hospital, Novosibirsk, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, 390039, Russian Federation|Saratov State Medical University, Saratov, 410028, Russian Federation|Research Institute of Hematology and Blood Transfusion, St. Petersburg, 193024, Russian Federation|State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary #1, Volgograd, 400138, Russian Federation|Hospital Universitario Germans Trias i Pujol, Badalona, Cataluña, 08916, Spain|Hospital Clinic de Barcelona, Barcelona, Cataluña, 8036, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Cataluña, 8041, Spain|Hospital 12 de Octubre, Madrid, Madrid, Communidad De, 28041, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Communidad De, 28222, Spain|Hospital Universitario de La Princesa, Madrid, 28033, Spain|Gazi University Medical Faculty Gazi Hospital, Ankara, 06500, Turkey|Ankara University Medical Faculty, Ankara, 6590, Turkey|Istanbul University Istanbul Medical Faculty, Istanbul, 34093, Turkey|Ondokuz Mayis University Faculty of Medicine, Samsun, 55239, Turkey|Birmingham Heartlands Hospital, Birmingham, B9 5SS, United Kingdom|Kent and Canterbury Hospital, Canterbury, CT1 3NG, United Kingdom|University Hospital of Wales, Cardiff, CF14 4XW, United Kingdom|Dorset County Hospital, Dorchester, DT1 2JY, United Kingdom|St. James University Hospital, Leeds, LS9 7TF, United Kingdom|Royal Liverpool University Hospital, Liverpool, L7 8XP, United Kingdom|St Bartholomews Hospital, London, EC1A 7BE, United Kingdom|King's College Hospital, London, SE5 9RS, United Kingdom|Hammersmith Hospital, London, W12 0NN, United Kingdom|University College London, London, WC1E 6BT, United Kingdom|Christie Hospital, Manchester, M20 4BX, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, United Kingdom|Churchill Hospital, Oxford, OX3 7LE, United Kingdom|Royal Cornwall Hospital, Truro, TR1 3LJ, United Kingdom|New Cross Hospital, Wolverhampton, WV10 0QP, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/95/NCT01569295/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/95/NCT01569295/SAP_001.pdf"
